大洋生物
(003017)
| 流通市值：12.52亿 | | | 总市值：15.52亿 |
| 流通股本：6776.36万 | | | 总股本：8400.00万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 194,843,722.18 | 919,451,375.42 | 714,741,924.74 | 481,667,594.61 |
| 营业收入 | 194,843,722.18 | 919,451,375.42 | 714,741,924.74 | 481,667,594.61 |
| 二、营业总成本 | 179,798,524.45 | 874,476,844.81 | 689,420,155.68 | 465,502,845.59 |
| 营业成本 | 157,393,959.04 | 753,175,563.11 | 596,046,523.44 | 401,349,599.04 |
| 税金及附加 | 1,377,606.86 | 7,324,255.1 | 5,561,943.52 | 3,818,691.01 |
| 销售费用 | 1,739,190.2 | 9,821,601.66 | 7,191,042.9 | 4,511,848.22 |
| 管理费用 | 14,437,122.53 | 67,064,470.58 | 51,138,022.6 | 35,715,784.22 |
| 研发费用 | 6,625,360.56 | 39,215,227.46 | 30,959,515.47 | 20,200,626.86 |
| 财务费用 | -1,774,714.74 | -2,124,273.1 | -1,476,892.25 | -93,703.76 |
| 其中:利息费用 | 1,103,592.5 | 6,142,126.34 | 3,522,439.72 | 2,913,417.64 |
| 其中:利息收入 | 2,471,750.02 | 7,672,659.39 | 4,680,986.98 | 2,161,302.45 |
| 加:公允价值变动收益 | - | -1,477,676.98 | -1,477,676.98 | -883,791.12 |
| 加:投资收益 | -853,912.03 | 3,120,086.16 | 3,685,224.59 | 2,502,574.36 |
| 资产处置收益 | 3,841 | -170,682.17 | -245,510.35 | 58,597.89 |
| 资产减值损失(新) | -306,821.64 | -11,545,060.1 | -2,265,735.11 | -3,155,782.89 |
| 信用减值损失(新) | -1,461,145.49 | 1,538,494.82 | -332,159.39 | 467,590.63 |
| 其他收益 | 5,464,468.02 | 19,852,594.34 | 15,194,540.48 | 7,828,036.23 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 17,891,627.59 | 56,292,286.68 | 39,880,452.3 | 22,981,974.12 |
| 加:营业外收入 | 23,382.77 | 92,097.36 | 181,401.57 | 57,295.73 |
| 减:营业外支出 | 29,593.5 | 9,397,553.15 | 1,244,662.99 | 324,237.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 17,885,416.86 | 46,986,830.89 | 38,817,190.88 | 22,715,031.96 |
| 减:所得税费用 | 967,194.74 | -3,019,873.84 | -1,359,040.81 | -1,142,278.26 |
| 六、净利润 | 16,918,222.12 | 50,006,704.73 | 40,176,231.69 | 23,857,310.22 |
| 持续经营净利润 | 16,918,222.12 | 50,006,704.73 | 40,176,231.69 | 23,857,310.22 |
| 归属于母公司股东的净利润 | 16,918,222.12 | 50,006,704.73 | 40,176,231.69 | 23,857,310.22 |
| (一)基本每股收益 | 0.21 | 0.62 | 0.68 | 0.41 |
| (二)稀释每股收益 | 0.21 | 0.62 | 0.68 | 0.41 |
| 九、综合收益总额 | 16,918,222.12 | 50,006,704.73 | 40,176,231.69 | 23,857,310.22 |
| 归属于母公司股东的综合收益总额 | 16,918,222.12 | 50,006,704.73 | 40,176,231.69 | 23,857,310.22 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-24 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |